2025
Utility of Candidate Genes From an Algorithm Designed to Predict Genetic Risk for Opioid Use Disorder
Davis C, Jinwala Z, Hatoum A, Toikumo S, Agrawal A, Rentsch C, Edenberg H, Baurley J, Hartwell E, Crist R, Gray J, Justice A, Gelernter J, Kember R, Kranzler H, Muralidhar S, Moser J, Deen J, Tsao P, Gaziano J, Hauser E, Kilbourne A, Matheny M, Oslin D, Churby L, Whitbourne S, Brewer J, Shayan S, Selva L, Pyarajan S, Cho K, DuVall S, Brophy M, Stephens B, Connor T, Argyres D, Assimes T, Hung A, Kranzler H, Aguayo S, Ahuja S, Alexander K, Androulakis X, Balasubramanian P, Ballas Z, Beckham J, Bhushan S, Boyko E, Cohen D, Dellitalia L, Faulk L, Fayad J, Fujii D, Gappy S, Gesek F, Greco J, Godschalk M, Gress T, Gupta S, Gutierrez S, Harley J, Hamner M, Hurley R, Iruvanti P, Jacono F, Jhala D, Kinlay S, Landry M, Liang P, Liangpunsakul S, Lichy J, Mahan C, Marrache R, Mastorides S, Mattocks K, Meyer P, Moorman J, Morgan T, Murdoch M, Norton J, Okusaga O, Oursler K, Poon S, Rauchman M, Servatius R, Sharma S, Smith R, Sriram P, Strollo P, Tandon N, Villareal G, Walsh J, Wells J, Whittle J, Whooley M, Wilson P, Xu J, Yeh S, Bast E, Dryden G, Hogan D, Joshi S, Lo T, Morales P, Naik E, Ong M, Petrakis I, Rai A, Yen A. Utility of Candidate Genes From an Algorithm Designed to Predict Genetic Risk for Opioid Use Disorder. JAMA Network Open 2025, 8: e2453913. PMID: 39786773, PMCID: PMC11718552, DOI: 10.1001/jamanetworkopen.2024.53913.Peer-Reviewed Original ResearchConceptsOpioid use disorder riskElectronic health record dataHealth record dataInternational Classification of DiseasesOpioid use disorderClassification of diseasesGenetic variantsInternational ClassificationGenetic riskRecord dataRisk of opioid use disorderMillion Veteran ProgramOpioid use disorder diagnosisUse disorderCase-control studyVeteran ProgramMain OutcomesDiagnostic codesClinical careOpioid exposurePharmacy recordsLogistic regressionRisk allelesNagelkerke R2Clinically useful model
2024
Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.Peer-Reviewed Original ResearchConceptsElectronic health recordsCancer diagnosisClinical data linkageMedicine Clinical TermsPatterns of careProstate cancer diagnosisRadical prostatectomyCancer risk stratificationData linkageHealth recordsClinical dataMain OutcomesCancer outcomesClinical juncturesClinical careCommon Procedural Terminology codesAdministrative dataDiagnosis codesLongitudinal clinical dataCohort studyPharmacy recordsGenomic classifierProcedural Terminology codesDevelopment of prostate cancer metastasisLinkage data
2021
HIV care using differentiated service delivery during the COVID‐19 pandemic: a nationwide cohort study in the US Department of Veterans Affairs
McGinnis KA, Skanderson M, Justice AC, Akgün KM, Tate JP, King JT, Rentsch CT, Marconi VC, Hsieh E, Ruser C, Kidwai‐Khan F, Yousefzadeh R, Erdos J, Park LS. HIV care using differentiated service delivery during the COVID‐19 pandemic: a nationwide cohort study in the US Department of Veterans Affairs. Journal Of The International AIDS Society 2021, 24: e25810. PMID: 34713585, PMCID: PMC8554215, DOI: 10.1002/jia2.25810.Peer-Reviewed Original ResearchConceptsVeterans AffairsClinic visitsCohort studyVL testARV coverageCOVID-19 pandemicVeterans Aging Cohort StudyHIV healthcare deliveryNationwide cohort studyAging Cohort StudyViral load testsDifferentiated service deliveryHealthcare deliveryHIV careMost patientsPharmacy recordsVL testingCalendar periodHealthcare encountersOverall healthARVVirtual healthcareVirtual visitsVisitsService deliveryClinical prediction of extra-medical use of prescription pain relievers from a representative United States sample
Thompson CL, Alcover KC, Yip SW. Clinical prediction of extra-medical use of prescription pain relievers from a representative United States sample. Preventive Medicine 2021, 149: 106610. PMID: 33989674, DOI: 10.1016/j.ypmed.2021.106610.Peer-Reviewed Original ResearchConceptsExtra-medical usePrescription pain relieversRepresentative United States sampleHealth administrative dataAnnual cross-sectional surveyHistory of depressionCross-sectional surveyPast-year useReceiver operator curveLogistic regression modelsUnited States population sampleUS National SurveyPharmacy recordsOpioid dependencePrescription opioidsPrescription painPeak incidencePain relieversClinical utilityPsychiatric historyDrug useOperator curveClinical predictionMedical guidanceMedical services
2018
High prevalence of non-adherence to antiretroviral therapy among undisclosed HIV-infected children in Ghana
Nichols JS, Kyriakides TC, Antwi S, Renner L, Lartey M, Seaneke OA, Obeng R, Catlin AC, Gan G, Reynolds NR, Paintsil E, Team O. High prevalence of non-adherence to antiretroviral therapy among undisclosed HIV-infected children in Ghana. AIDS Care 2018, 31: 25-34. PMID: 30235940, PMCID: PMC6288009, DOI: 10.1080/09540121.2018.1524113.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyART adherence ratesPediatric HIV carePrevalence of adherenceAntiretroviral medication adherenceCohort of childrenHIV-positive statusChildren of caregiversChild-caregiver dyadsHIV carePharmacy recordsRefill dataMedian adherenceMedication adherenceAdherence ratesPoor adherenceHigh prevalencePositive statusIntervention studiesHIVGood adherenceAdherenceBaseline dataChildrenTherapy
2017
Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost.
Kaplan D, Yu S, Taddei T, Reiss K, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost. Journal Of Clinical Oncology 2017, 35: 385-385. DOI: 10.1200/jco.2017.35.4_suppl.385.Peer-Reviewed Original ResearchDuration of exposureBCLC BICD9 codesBarcelona Clinic Liver Cancer stageInitiation of sorafenibMedian overall survivalLiver Cancer stageLonger exposure durationECOG PSExposure durationUp-titrationChild-TurcotteMELD scoreSorafenib therapyFirst doseOverall survivalPharmacy recordsMedian agePrescription fillsLiver diseaseTumor numberC-HCCEquivalent survivalHCC patientsCancer stageSorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival.
Kaplan D, Taddei T, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Sorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival. Journal Of Clinical Oncology 2017, 35: 404-404. DOI: 10.1200/jco.2017.35.4_suppl.404.Peer-Reviewed Original ResearchICD9 codesBarcelona Clinic Liver Cancer stageOverall median survival rateInitial dosing regimensLiver Cancer stageMedian survival rateSimilar treatment durationCTP AECOG PSExtrahepatic spreadChild-TurcotteMacrovascular invasionMELD scorePrescriber specialtyReal-world practiceMedian agePharmacy recordsSorafenib exposureBCLC 0Dosing regimensLiver diseaseTumor numberPrescribing practicesHCC patientsCancer stage
2016
Natural Language Processing for Understanding Contraceptive Use at the VA
Scotch M, Brandt C, Leung S, Womack J. Natural Language Processing for Understanding Contraceptive Use at the VA. Annals Of Information Systems 2016, 19: 249-259. DOI: 10.1007/978-3-319-23294-2_12.Peer-Reviewed Original ResearchSelf-reported contraceptive useWomen Veterans Cohort StudyElectronic health recordsContraceptive useFemale veteransRetrospective chart reviewVA electronic health recordHealthcare facilitiesChart reviewCohort studyPharmacy recordsMedical recordsDrug FileContraceptive informationPatientsContraceptivesHealth recordsGold standardPermanent methodsNatural language processing pipelineVeteransCareAdditional researchLanguage processing pipelineVA
2015
Mental Health Treatment for Older Veterans Newly Diagnosed with PTSD: A National Investigation
Smith NB, Cook JM, Pietrzak R, Hoff R, Harpaz-Rotem I. Mental Health Treatment for Older Veterans Newly Diagnosed with PTSD: A National Investigation. American Journal Of Geriatric Psychiatry 2015, 24: 201-212. PMID: 25772341, DOI: 10.1016/j.jagp.2015.02.001.Peer-Reviewed Original ResearchConceptsMental health treatmentPosttraumatic stress disorderOlder veteransVA healthcare systemHealth treatmentClinical characteristicsDecreased oddsNational administrative data setVeterans AffairsMental health service utilizationAppropriate mental health treatmentOdds of treatmentMental health visitsHealth service utilizationHealthcare systemPharmacy recordsHealth visitsCox regressionPsychiatric comorbidityPsychotherapy visitsService utilizationLarge cohortMedical appointmentsAdministrative data setsNew diagnosis
2013
National psychotropic prescription dispensation among dually diagnosed patients
Marienfeld C, Rosenheck R. National psychotropic prescription dispensation among dually diagnosed patients. Advances In Dual Diagnosis 2013, 6: 34-44. DOI: 10.1108/17570971311309015.Peer-Reviewed Original ResearchAnalysis of covarianceNational Veterans Health AdministrationOutpatient mental health visitsMental health service useMental health visitsHealth service useVeterans Health AdministrationSevere mental illnessDrug-drug interactionsSchizophrenia spectrum disordersPrescription dispensationMedication classesClinic visitsClinical confoundersPharmacy recordsHealth visitsPsychotropic prescriptionsMood stabilizersPsychotropic medicationsMore prescriptionsHigh riskPatientsService useHealth AdministrationBipolar disorder
2011
A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected Versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans
Butt AA, McGinnis K, Skanderson M, Justice AC. A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected Versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans. AIDS Research And Human Retroviruses 2011, 27: 973-979. PMID: 21338329, PMCID: PMC3719436, DOI: 10.1089/aid.2011.0004.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseHepatitis C virusDecompensated liver diseaseHCV-HIVTreatment eligibilityC virusCohort of HCVVA National Patient Care DatabaseNational Patient Care DatabasePharmacy Benefits Management databaseHCV treatment eligibilityHCV-HIV coinfectionRecent alcohol abuseHCV/HIVCurrent treatment guidelinesProportion of patientsObstructive pulmonary diseaseCoronary artery diseasePatient Care DatabaseActual clinical settingsCoinfected PersonsAggressive managementCommon contraindicationsPharmacy recordsRenal failure
2009
Hepatitis C treatment completion rates in routine clinical care
Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver International 2009, 30: 240-250. PMID: 19889081, PMCID: PMC3132089, DOI: 10.1111/j.1478-3231.2009.02156.x.Peer-Reviewed Original ResearchConceptsPre-treatment anemiaTreatment completion ratesVA National Patient Care DatabaseHuman immunodeficiency virus (HIV) coinfectionNational Patient Care DatabasePharmacy Benefits Management databaseHepatitis C virus infectionCompletion ratesHigher comorbidity countC virus infectionImmunodeficiency virus coinfectionCoronary artery diseasePatient Care DatabaseRoutine clinical careClinical practice settingTreatment sitesInitiate therapyInterferon useComorbidity countPharmacy recordsStandard interferonArtery diseaseVirus coinfectionMultivariable analysisCare database
2008
Predictors of Adherence to Antiretroviral Therapy in Rural Zambia
Carlucci JG, Kamanga A, Sheneberger R, Shepherd BE, Jenkins CA, Spurrier J, Vermund SH. Predictors of Adherence to Antiretroviral Therapy in Rural Zambia. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2008, 47: 615-622. PMID: 18209678, PMCID: PMC2743102, DOI: 10.1097/qai.0b013e318165dc25.Peer-Reviewed Original ResearchConceptsRural health facilitiesHIV/AIDS careRural ZambiaBetter clinical outcomesBody mass indexHIV drug resistancePredictors of adherenceResource-limited settingsAntiretroviral therapyAIDS stagePatient demographicsPill countPharmacy recordsClinical outcomesMass indexAdherence ratesClinical indicesAIDS careAdherence levelsHealth facilitiesOptimize outcomesPatient's homeMission hospitalPatientsStudy participants
2006
Complications and Antireflux Medication Use After Antireflux Surgery
Dominitz J, Dire C, Billingsley K, Todd–Stenberg J. Complications and Antireflux Medication Use After Antireflux Surgery. Clinical Gastroenterology And Hepatology 2006, 4: 299-305. PMID: 16527692, DOI: 10.1016/j.cgh.2005.12.019.Peer-Reviewed Original ResearchConceptsAntireflux medication useAntireflux surgeryMedication useAntireflux medicationVeterans Affairs administrative databasesPredictors of complicationsGastroesophageal reflux diseaseMore outpatient visitsSurgical mortality rateHealth care useH2-receptor antagonistsPostoperative complicationsPromotility agentsReflux diseasePharmacy recordsOutpatient visitsEsophageal cancerReceptor antagonistCare useAdministrative databasesMultiple prescriptionsComplicationsPatientsMortality rateSurgery
2003
Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma
Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E. Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma. Cancer 2003, 97: 2972-2977. PMID: 12784331, DOI: 10.1002/cncr.11436.Peer-Reviewed Original ResearchConceptsPercent of patientsMetastatic breast carcinomaTrastuzumab-based therapyCentral nervous system metastasesCentral nervous system diseaseNervous system metastasesCNS diseaseNervous system diseasesBreast carcinomaBrain metastasesCNS metastasesLeptomeningeal involvementSystem diseasesDisease sitesMore brain metastasesParenchymal brain metastasesProgressive CNS diseaseFirst-line therapyTime of diagnosisMedian survival periodBlood-brain barrierNew treatment strategiesStable diseaseMetastatic diseasePharmacy records
1997
Risk Factors for Postherpetic Neuralgia
Choo PW, Galil K, Donahue JG, Walker AM, Spiegelman D, Platt R. Risk Factors for Postherpetic Neuralgia. JAMA Internal Medicine 1997, 157: 1217-1224. PMID: 9183233, DOI: 10.1001/archinte.1997.00440320117011.Peer-Reviewed Original ResearchConceptsOnset of zosterPostherpetic neuralgiaRisk factorsHerpes zosterCases of PHNTreatment of zosterHealth maintenance organizationSystemic acyclovirSystemic corticosteroidsElderly patientsPharmacy recordsCommon complicationSensory symptomsProdromal symptomsHigh prevalenceZosterEligibility criteriaMaintenance organizationPatientsPrevalenceTreatment factorsCorticosteroidsNeuralgiaAcyclovirSymptoms
1987
Gender Differences in the Acquisition of Prescribed Drugs
Svarstad B, Cleary P, Mechanic D, Robers P. Gender Differences in the Acquisition of Prescribed Drugs. Medical Care 1987, 25: 1089-1098. PMID: 3695639, DOI: 10.1097/00005650-198711000-00007.Peer-Reviewed Original ResearchConceptsMore prescribed drugsPrescribed drugsFemale-specific conditionsChild-bearing yearsSelf-reported drug usePharmacy recordsDrug categoriesGender differencesDrug useMedical careAge groupsStudy periodWomenDrugsHigh anxietyPhysiciansMenPrevious studiesDifferencesGross measuresIllnessReproductive rolesDiagnosisCare
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply